SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial
Paciente / Población Intervención / Exposición Comparación Desenlace
In 2,521 patients with heart failure (NYHA II–III, EF ≤ 35 %), an implantable defibrillator reduced all-cause mortality compared with placebo or amiodarone.
N
2521
Diseño
RCT, double-blind drug arms
Desenlace
All-cause mortality
Relevancia
1
ResultadoICD HR 0.77; amiodarone no better than placebo.
Bardy GH, et al. N Engl J Med. 2005;352(3):225-237. 10.1056/NEJMoa043399
Discusión y crítica
Extended ICD benefit to non-ischaemic HF and showed amiodarone is not prognostically useful. The benefit was concentrated in NYHA class II.